$5.00
Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Positive Signs As Multiple Insiders Buy Rezolute Stock
Overview
52-week range
$1.07
$11
38% of range
Avg surprise (last 2)
-22.9%
Avg reaction (last 2)
+1.2%
50% positive
Latest IV / EM
109%
EM ±25.0% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.16 | $-0.13 | -23.1% | +40.7% | +4.1% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $-0.22 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.18 | — | — | — | — | financials |
| Tue May 13, 2025 | Mar/2025 | $-0.27 | $-0.22 | -22.7% | — | -1.6% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-0.22 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-0.22 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.34 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.27 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.28 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-17M | $-24M | $-20M | — | $-20M | $-17M | $-17M | — |
| Net income | $-16M | $-23M | $-18M | — | $-19M | $-16M | $-15M | — |
| EPS (diluted) | $-0.16 | $-0.22 | $-0.18 | — | $-0.27 | $-0.22 | $-0.22 | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11M | $12M | $9M | $94M | $15M | $9M | $10M | $70M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $122M | $135M | $155M | $171M | $89M | $99M | $110M | $129M |
| Total assets | $125M | $139M | $159M | $175M | $95M | $112M | $123M | $133M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $9M | $11M | $11M | $13M | $12M | $12M | $10M | $12M |
| Total equity | $117M | $128M | $147M | $162M | $83M | $100M | $113M | $121M |